- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06868212
Badanie w celu oceny skuteczności remibrutynibu w porównaniu z dupilumabem we wczesnych punktach czasowych u dorosłych z przewlekłą spontaniczną pokrzywką nieodpowiednio kontrolowaną przez h1-antyhistaminy drugiej generacji (RECLAIM)
US Faza 3B, wieloośrodkowa, randomizowane, podwójnie ślepe, podwójnie ślepe badanie w celu oceny skuteczności remibrutynibu w porównaniu z dupilumabem we wczesnych punktach czasowych u dorosłych z przewlekłą spontaniczną pokrzywką nieodpowiednio kontrolowaną przez H1-antihistamin drugiej generacji H1
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily [b.i.d.] by mouth [p.o.]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihistamines (sgH1-AH) (standard label dose as background therapy) in adult US participants with moderate to severe chronic spontaneous urticaria (CSU) inadequately controlled by sgH1-AHs.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This study consists of a screening period (up to 4 weeks), a core treatment period (12 weeks double-blind, double-dummy), an optional open-label extension [OLE] period, and safety follow-up period.
Screening period: participants will have a screening period of a minimum of 7 days up to a maximum of 28 days to establish eligibility for the study. Participants meeting all the inclusion criteria and none of the exclusion criteria will be eligible to participate in the study.
Core treatment period (double-blind, double-dummy): approximately, 400 participants diagnosed with CSU inadequately controlled by sgH1-AH will be randomized in this study. Participants will be stratified based on prior exposure to anti-IgE biologics.
Eligible participants will be randomized in a 1:1 ratio to receive remibrutinib and placebo solution for injection or dupilumab and remibrutinib matching placebo, both as an add-on treatment to once daily standard label dose of sgH1-AH background therapy, until the Week 12 visit.
Additionally, all participants will be on a stable, standard label dose of a sgH1-AH ("background therapy") throughout the entire core treatment period (starting a minimum of 7 days prior to randomization until the end of Week 12). To treat unbearable symptoms of CSU, participants will be allowed to add more of the same sgH1-AH on an as-needed basis ("rescue therapy"). The total maximum daily dose of sgH1-AH (background plus rescue) should not exceed 4 tablets/day (4-fold the standard label dose).
Optional open-label extension [OLE] period: At the end of the 12-week double-blind treatment period, and in case remibrutinib is not commercially available, participants from both arms will be given the choice to roll over into an optional OLE safety period and receive remibrutinib (25 mg b.i.d. p.o.) for 12 weeks (up to Week 24).
Safety follow-up period:
- For participants who do not enter the OLE period: there will be a safety follow-up for 12 weeks with safety follow-up phone calls at Week 16 and Week 24 (Week 24 will be end of study).
- For participants who enter the OLE period: there will be 2 options at the end of Week 24:
- If remibrutinib is commercially available: participants will discontinue study treatment, perform their EOT visit and receive a safety follow-up phone call 4 weeks after the last dose of remibrutinib (this will be the EOS).
- If remibrutinib is not commercially available, participants may continue on remibrutinib 25 mg b.i.d. until its commercial availability and return for site visits for safety follow up and treatment dispensation every 3 months. When remibrutinib becomes commercially available, the participant will be contacted for a site visit to complete the EOT visit and will receive a safety follow-up phone call 4 weeks after the last dose of remibrutinib (this will be the EOS).
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35209
- Allervie Clinical Research
-
Birmingham, Alabama, Stany Zjednoczone, 35244
- Cahaba Derm and skin hlth ctr 27
-
-
Arizona
-
Litchfield Park, Arizona, Stany Zjednoczone, 85340
- Research Solutions of Arizona
-
Payson, Arizona, Stany Zjednoczone, 85541
- Peak Dermatology
-
Phoenix, Arizona, Stany Zjednoczone, 85032
- Premier Allergy Asthma And Immunology
-
Scottsdale, Arizona, Stany Zjednoczone, 85254
- Orso Health
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72205
- Acuro Research Inc
-
-
California
-
Fountain Valley, California, Stany Zjednoczone, 92708
- First OC Dermatology
-
Fremont, California, Stany Zjednoczone, 95438
- Ctr for Dermatology Clinical Res
-
Huntington Beach, California, Stany Zjednoczone, 92647
- Allergy and Asthma Specialists Group
-
Long Beach, California, Stany Zjednoczone, 90808
- Orso Health
-
Long Beach, California, Stany Zjednoczone, 90815
- Ark Clinical Research
-
Los Angeles, California, Stany Zjednoczone, 90045
- Dermatology Research Associates
-
Los Angeles, California, Stany Zjednoczone, 90025
- California Allergy and Asthma Medical Group
-
Napa, California, Stany Zjednoczone, 94558
- One Of A Kind Clinical Research
-
Palo Alto, California, Stany Zjednoczone, 94304
- Stanford University Medical Center
-
Pomona, California, Stany Zjednoczone, 91767
- Empire Clinical Research
-
Redwood City, California, Stany Zjednoczone, 94063
- Allergy and Asthma Consultants
-
Rocklin, California, Stany Zjednoczone, 95765
- Norcal Clinical Research
-
Rolling Hills Estates, California, Stany Zjednoczone, 90274
- Peninsula Research Associates
-
Sacramento, California, Stany Zjednoczone, 95815
- Integrative Skin Science and Res
-
Sacramento, California, Stany Zjednoczone, 95817
- UC Davis Neuromuscular Research Center
-
San Diego, California, Stany Zjednoczone, 92123
- Therapeutics Clinical Research
-
Santa Monica, California, Stany Zjednoczone, 90403
- Dermatology Institute and Skin Care
-
Upland, California, Stany Zjednoczone, 91786
- Integrated Research of Inland Inc
-
Walnut Creek, California, Stany Zjednoczone, 94598
- Allergy and Asthma Clin Res Inc
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- University of Colorado Hospital - Aurora
-
Colorado Springs, Colorado, Stany Zjednoczone, 80909
- Colorado ENT and Allergy
-
Colorado Springs, Colorado, Stany Zjednoczone, 80907
- Asthma and Allergy Associates P C
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20059
- Howard University Hospital Division of Geriatrics
-
-
Florida
-
Aventura, Florida, Stany Zjednoczone, 33180
- Florida Ctr Allergy Asthma Research
-
Boca Raton, Florida, Stany Zjednoczone, 33486
- Skin Care Research Inc
-
Doral, Florida, Stany Zjednoczone, 33172
- Omnicure Clinical Research
-
Fort Lauderdale, Florida, Stany Zjednoczone, 33308
- FXM Clinical Research Ft Laud
-
Hollywood, Florida, Stany Zjednoczone, 33021
- Skin Care Research LLC
-
Jacksonville, Florida, Stany Zjednoczone, 32216
- Jacksonville Center for Clinical Research
-
Miami, Florida, Stany Zjednoczone, 33176
- Miami Dade Medical Research
-
Miami, Florida, Stany Zjednoczone, 33125
- University of MiamiHealth System
-
Miami, Florida, Stany Zjednoczone, 33175
- FXM Clinical Res Miami LLC
-
Miramar, Florida, Stany Zjednoczone, 33027
- Eminat LLC
-
North Miami Beach, Florida, Stany Zjednoczone, 33162
- Ziaderm Research LLC
-
Panama, Florida, Stany Zjednoczone, 32405
- AllerVie Health
-
Sarasota, Florida, Stany Zjednoczone, 34233
- Sarasota Clinical Research
-
Sweetwater, Florida, Stany Zjednoczone, 33172
- Lenus Research and Med Group LLC
-
Tampa, Florida, Stany Zjednoczone, 33613
- Asthma Allergy Immunology Clin Res
-
Winter Park, Florida, Stany Zjednoczone, 32789
- Conquest Research
-
-
Georgia
-
Columbus, Georgia, Stany Zjednoczone, 31904
- AllerVie Clin Res Columbus GA
-
Cumming, Georgia, Stany Zjednoczone, 30040
- Cleaver Medical Group
-
Douglasville, Georgia, Stany Zjednoczone, 30135
- Southeast Dermatology Specialists
-
Savannah, Georgia, Stany Zjednoczone, 31406
- Aeroallergy Research Laboratories
-
-
Idaho
-
Meridian, Idaho, Stany Zjednoczone, 83642
- The Allergy Group-Meridian Clinic
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60612
- Rush University Medical Center
-
Chicago, Illinois, Stany Zjednoczone, 60611
- NW Uni C and T Sciences Ins
-
Normal, Illinois, Stany Zjednoczone, 61761
- Midwest Allergy Sinus Asthma SC
-
O'Fallon, Illinois, Stany Zjednoczone, 62269
- Clinical Res Ctr of S Illinois
-
River Forest, Illinois, Stany Zjednoczone, 60305
- Asthma and Allergy Center of Chicago S C
-
Skokie, Illinois, Stany Zjednoczone, 60077
- Endeavor Health Clinical Trials Center
-
Wheaton, Illinois, Stany Zjednoczone, 60189
- Accellacare Duly Health and Care
-
-
Indiana
-
Evansville, Indiana, Stany Zjednoczone, 47715
- Deaconess Clin Allerg Res Inst
-
New Albany, Indiana, Stany Zjednoczone, 47150
- Southern IN Clinical Trials
-
-
Iowa
-
Ames, Iowa, Stany Zjednoczone, 50010
- McFarland Clinic PC
-
-
Kentucky
-
Bowling Green, Kentucky, Stany Zjednoczone, 42104
- Equity Medical LLC
-
Louisville, Kentucky, Stany Zjednoczone, 40215
- Family Allergy And Asthma Rsch Inst
-
Owensboro, Kentucky, Stany Zjednoczone, 42301
- Allergy and Asthma Specialist P S C
-
-
Louisiana
-
Baton Rouge, Louisiana, Stany Zjednoczone, 70816
- Ochsner Health Center
-
Lafayette, Louisiana, Stany Zjednoczone, 70508
- Velocity Clinical Research
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21236
- Chesapeake Clinical Research Inc
-
Baltimore, Maryland, Stany Zjednoczone, 21205
- Johns Hopkins U School of Med
-
Chevy Chase, Maryland, Stany Zjednoczone, 20815
- Institute for Asthma and Allergy PC
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02111
- Boston Specialists LLC
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48106-0525
- ClinSite Inc
-
Caledonia, Michigan, Stany Zjednoczone, 49316
- Derm Institute West Michigan PLLC
-
Detroit, Michigan, Stany Zjednoczone, 48202
- Henry Ford Hospital
-
Troy, Michigan, Stany Zjednoczone, 48084
- Somerset Skin Centre
-
Troy, Michigan, Stany Zjednoczone, 48084
- Revival Research Institute
-
-
Minnesota
-
Minneapolis, Minnesota, Stany Zjednoczone, 55455
- University of Minnesota
-
Minneapolis, Minnesota, Stany Zjednoczone, 55402
- Clinical Research Institute
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Mayo Clinic - Rochester
-
-
Missouri
-
Columbia, Missouri, Stany Zjednoczone, 65201
- ENT and Allergy Center of Missouri
-
St Louis, Missouri, Stany Zjednoczone, 63141
- The Clinical Research Center
-
St Louis, Missouri, Stany Zjednoczone, 63141
- Washington University
-
-
Nebraska
-
Lincoln, Nebraska, Stany Zjednoczone, 68510
- Somnos Clinical Research
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89144
- Las Vegas Dermatology
-
Las Vegas, Nevada, Stany Zjednoczone, 89128
- Allergy and Asthma Center of Las Vegas
-
-
New Jersey
-
Hamilton, New Jersey, Stany Zjednoczone, 08619
- Circuit Clinical Mercer Algy Pulm
-
Little Silver, New Jersey, Stany Zjednoczone, 07739
- Allergy Asthma Assoc Monmouth
-
Ocean Township, New Jersey, Stany Zjednoczone, 07712
- Allergy Partners of New Jersey PC
-
-
New York
-
The Bronx, New York, Stany Zjednoczone, 10467
- Montefiore Medical Center
-
The Bronx, New York, Stany Zjednoczone, 10455
- Equity Medical
-
-
North Carolina
-
Asheville, North Carolina, Stany Zjednoczone, 28801
- Allergy Partners Of West NC
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27516
- UNC DermatologyandSkinCancer Ctr
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45231
- Bernstein Clinical Research Center
-
Columbus, Ohio, Stany Zjednoczone, 43213
- CR Services Acquisition US
-
Fairborn, Ohio, Stany Zjednoczone, 45324
- Wright State University
-
Toledo, Ohio, Stany Zjednoczone, 43617
- Toledo Institute of Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73118
- Unity Clinical Research
-
Tulsa, Oklahoma, Stany Zjednoczone, 74136
- Vital Prospects Clinical Research Institute
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97239
- Oregon Health Sciences University
-
Portland, Oregon, Stany Zjednoczone, 97223
- Oregon Medical Research Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15213
- University of Pittsburgh Medical Center
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15241
- Allergy and Clinical Immunology Associates
-
-
South Carolina
-
Greenville, South Carolina, Stany Zjednoczone, 29607
- Allergic Disease and Asthma Center
-
Greenville, South Carolina, Stany Zjednoczone, 29601
- Tribe Clinical Research LLC
-
North Charleston, South Carolina, Stany Zjednoczone, 29420
- National Allergy and Asthma Research LLS
-
North Charleston, South Carolina, Stany Zjednoczone, 29406
- Charleston ENT and Allergy
-
-
Tennessee
-
Goodlettsville, Tennessee, Stany Zjednoczone, 37072-2301
- Goodlettsville Dermatology Research
-
Murfreesboro, Tennessee, Stany Zjednoczone, 37130
- International Clinical Research Tennessee LCC
-
-
Texas
-
Arlington, Texas, Stany Zjednoczone, 76011
- Arlington Center for Dermatology
-
Austin, Texas, Stany Zjednoczone, 78759
- Orion Clinical Research
-
Bellaire, Texas, Stany Zjednoczone, 77401
- Bellaire Dermatology Associates
-
Dallas, Texas, Stany Zjednoczone, 75230
- Reveal Research Institute
-
Dallas, Texas, Stany Zjednoczone, 75231
- Pharma Research and Amp Consult
-
El Paso, Texas, Stany Zjednoczone, 79924
- Western Sky Medical Research
-
Houston, Texas, Stany Zjednoczone, 77030
- Center for Clinical Studies
-
Kerrville, Texas, Stany Zjednoczone, 78028
- Sante Clinical Research
-
San Antonio, Texas, Stany Zjednoczone, 78229
- Andante Research
-
San Antonio, Texas, Stany Zjednoczone, 78213
- RFSA Dermatology
-
-
Utah
-
Murray, Utah, Stany Zjednoczone, 84107
- University Of Utah
-
Sandy City, Utah, Stany Zjednoczone, 84093
- Allergy Associates of Utah
-
-
Virginia
-
Vienna, Virginia, Stany Zjednoczone, 22182
- Forefront Dermatology
-
-
Washington
-
Bellingham, Washington, Stany Zjednoczone, 98225
- Bellingham Asthma Allergy and Immunology
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Adults ≥ 18 years of age at the time of signing the informed consent
- CSU duration for ≥ 6 months prior to screening (defined as the onset of CSU determined by the Investigator based on all available supporting documentation)
- Diagnosis of CSU inadequately controlled by sgH1-AH at the time of randomization, defined as:
- The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despite the use of sgH1-AH during the 7 days prior to randomization (Day 1):
- UAS7 score (range, 0-42) ≥ 16, and
- ISS7 score (range, 0-21) ≥ 6, and
- HSS7 score (range, 0-21) ≥ 6
- Documentation of hives within 3 months before randomization (either at screening and/or at randomization); or documented in the participants medical history
- Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol
- Participants must not have had more than one missing UPDD entry (either morning or evening) in the 7 days prior to randomization (Day 1)
Exclusion Criteria:
- Previous use of remibrutinib or other bruton's tyrosine kinase (BTK) inhibitors
- Previous use of dupilumab
- Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension within 12 months prior to Visit 1), neurological, psychiatric, pulmonary, renal, hepatic (past history or current), endocrine or metabolic disorder, or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.
- Evidence of hematological disorders (including coagulation disorders or significant bleeding risk)
- History or evidence of gastrointestinal disease (including gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAID), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion)
- Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
- Requirement for anticoagulant medication (for example, warfarin or Novel Oral Anti-Coagulants [NOAC])
- History or current hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or hepatic parameters at screening: Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) levels more than 1.5x ULN or International Normalized Ratio (INR) > 1.5 at screening
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Treatment group 1: Remibrutinib + Placebo
Remibrutinib tablet (25 mg b.i.d. p.o.) + placebo solution for injection in pre-filled syringe (2 s.c. injections at baseline and then 1 s.c. injection every other week [Weeks 2-10]) |
Film-coated tablet, oral administration, 25 mg b.i.d. Solution for injection in pre-filled syringe every 2 weeks |
|
Aktywny komparator: Treatment group 2: Dupilumab + remibrutinib matching placebo
Dupilumab pre-filled syringe (600 mg loading dose [2 x 300 mg dupilumab s.c. injection] at baseline visit followed by dupilumab 300 mg s.c. injection every other week [Weeks 2-10]) + remibrutinib matching placebo tablet (1 tablet b.i.d. p.o.) |
Film-coated tablet, oral administration, b.i.d. Solution for injection in pre-filled syringe 600 mg loading dose followed by 300 mg dose every 2 weeks |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Absolute change from baseline in Weekly Urticaria Activity Score (UAS7) at Week 4
Ramy czasowe: Baseline, Week 4
|
The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Baseline, Week 4
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Improvement of severity of hives, assessed as absolute change from baseline in HSS7 score at Week 4
Ramy czasowe: Baseline, Week 4
|
The hives (wheals) severity score, defined by number of hives, will be recorded by the participant twice daily in their eCOA device, on a scale of 0 (none) to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21. |
Baseline, Week 4
|
|
Improvement of severity of itch, assessed as absolute change from baseline in ISS7 score at Week 4
Ramy czasowe: Baseline, Week 4
|
The severity of the itch will be recorded by the participant twice daily in their eCOA device, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 - 21. |
Baseline, Week 4
|
|
Improvement of UAS7, assessed as absolute change from baseline in UAS7 score at Week 1
Ramy czasowe: Baseline, Week 1
|
The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Baseline, Week 1
|
|
Percentage of participants with UAS7 ≤ 6 at Week 4
Ramy czasowe: Week 4
|
Percentage of participants who achieved UAS7 ≤ 6 at Week 4. The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Week 4
|
|
Percentage of participants with UAS7=0 at Week 4
Ramy czasowe: Week 4
|
Percentage of participants who achieved UAS7 = 0 at Week 4. The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Week 4
|
|
Percentage of participants with UAS7 ≤ 6 at Week 2
Ramy czasowe: Week 2
|
Percentage of participants who achieved UAS7 ≤ 6 at Week 2. The UAS7 is the sum of the Weekly Hives Severity (HSS7) score and the Weekly Itch Severity (ISS7) score, and ranges from 0-42. Weekly scores (HSS7 and ISS7 scores) will be derived by adding up the average daily scores of the 7 days preceding the visit. |
Week 2
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Procesy patologiczne
- Przewlekła choroba
- Atrybuty choroby
- Choroby układu odpornościowego
- Nadwrażliwość, natychmiastowa
- Nadwrażliwość
- Choroby skórne
- Pokrzywka
- Choroby skóry, naczyniowe
- Stany patologiczne, oznaki i objawy
- Choroby skóry i tkanki łącznej
- Przewlekła pokrzywka
- Lecznictwo
- Drogi podawania leków
- Terapia lecznicza
- Zastrzyki
- Dupilumab
- remibrutynib
Inne numery identyfikacyjne badania
- CLOU064AUS02
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .